| Name
|
Octreotide (SMS 201-995)
|
| Other Name
|
Somatostatin analogue
|
| 序列（单字母缩写）
|
|
| Sequence (Single letter abbreviations)
|
d-PHE}{CYS}{PHE}{d-TRP}{LYS}{THR}{CYS}{THR}-OL
|
| C-port
|
OL
|
| Chemical bridge
|
Cys2-Cys7
|
| Basic description
|
SMS 201-995 belongs to somatostatin analog that is three times more potent than the native hormone in inhibiting the secretion of growth hormone. SMS 201-995 can lower plasma concentrations of growth hormone and somatomedin-C in patients with pituitary acromegaly. Somatostatin analogues have been suggested as possible therapy for human pancreatic cancer.
|
| Solubility
|
The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents.
|
| The molecular weight
|
1019.240
|
| Chemical formula
|
C49H66N10O10S2
|
| The purity
|
> 95%
|
| Storage conditions
|
Before use, store the peptide in the DRY form at 0°C - 5°C. For and more repeatable results, rehydrate the peptide immediately before use. Do not re-freeze any unused portions.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
Muhvic D, et al. Induction of experimental allergic encephalomyelitis in a low-susceptible Albino Oxford rat strain by somatostatin analogue SMS 201-995. Neuroimmunomodulation. 2005; 12(1): 20-28.
Massari D, et al. SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line. Anticancer Drugs. Oct 2005; 16(9): 989-996.
|
Octreotide (SMS 201-995)
